These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30038044)

  • 21. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
    Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
    [No Abstract]   [Full Text] [Related]  

  • 22. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Hsu YC; Wei MT; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Real-World Study on Safety and Efficacy of TAF Treatment in HBV Patients with High Risk of Osteoporosis or Osteopenia in China.
    Li C; Li H; Gong M; Liu Y; Zhang R; Geng J; Wang H; Yu Z; Wang Z; Liu X; Wei J
    Altern Ther Health Med; 2024 Sep; 30(9):146-151. PubMed ID: 38294749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
    Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
    J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
    Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
    Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Buti M; Marcos-Fosch C; Esteban R
    Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of chronic hepatitis B: virological and pharmacological aspects].
    Foucault T; Handala L; Paintaud G; Gaudy-Graffin C; Marlet J
    Virologie (Montrouge); 2022 May; 26(3):228-239. PubMed ID: 35792839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
    Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
    Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
    Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
    Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
    Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
    [No Abstract]   [Full Text] [Related]  

  • 38. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Lim YS; Yoo BC; Byun KS; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 Jun; 65(6):1042-51. PubMed ID: 25800784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    Park ES; Lee AR; Kim DH; Lee JH; Yoo JJ; Ahn SH; Sim H; Park S; Kang HS; Won J; Ha YN; Shin GC; Kwon SY; Park YK; Choi BS; Lee YB; Jeong N; An Y; Ju YS; Yu SJ; Chae HB; Yu KS; Kim YJ; Yoon JH; Zoulim F; Kim KH
    J Hepatol; 2019 Jun; 70(6):1093-1102. PubMed ID: 30794889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.